Skip to content

Lyell Immunopharma, Inc.

LYEL

CIK 0001806952

← back to feed
Revenue (TTM)
$32K
−41.0% YoY Q1 May 2026
Net Income (TTM)
−$157.88M
+20.0% YoY Q1 May 2026
EPS Diluted (TTM)
−$9.66
+38.8% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-581,315.6%
Q1 May 2026
Net Margin
-493,368.8%
Q1 May 2026
Free Cash Flow (TTM)
−$183.37M
Q1 May 2026
Cash
$90.77M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
23.33M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings